<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01025830</url>
  </required_header>
  <id_info>
    <org_study_id>BETr</org_study_id>
    <nct_id>NCT01025830</nct_id>
  </id_info>
  <brief_title>Triomune Bioequivalence With Innovators</brief_title>
  <official_title>Steady State Bioequivalence of Generic and Innovator Formulations of Stavudine, Lamivudine, and Nevirapine in HIV-infected Ugandan Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Makerere University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Makerere University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The null hypothesis is that there is a difference in the the relative rate and extent of
      absorption into the systemic circulation of Triomune and brand-name
      Stavudine/Lamivudine/Nevirapine in HIV-infected Africans and the alternative hypothesis is
      that there is no difference in the the relative rate and extent of absorption into the
      systemic circulation of Triomune and brand-name Stavudine/Lamivudine/Nevirapine in
      HIV-infected Africans. This is a non-inferiority study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Generic antiretroviral therapy is the mainstay of HIV treatment in resource-limited settings,
      yet there is little evidence confirming the bioequivalence of generic and brand name
      formulations. We compared the steady-state pharmacokinetics of Lamivudine, Stavudine and
      Nevirapine in HIV-infected subjects who were receiving a generic formulation (Triomune速) or
      the corresponding brand formulations (Epivir速, Zerit速, and Viramune速). An open-label,
      randomized, crossover study was carried out in 18 HIV-infected Ugandan subjects stabilized on
      Triomune-40. Subjects received Lamivudine (150 mg), Stavudine (40 mg), and Nevirapine (200
      mg) in either the generic or brand formulation twice a day for 30 days, before switching to
      the other formulation. At the end of each treatment period, blood samples were collected over
      12 h for pharmacokinetic analysis. The main outcome measures were the mean AUC0-12h and Cmax.
      Bioequivalence was defined as a geometric mean ratio between the generic and brand-name
      within the 90% confidence interval of 0.8-1.25.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Concentration-Time Curve(AUC)</measure>
    <time_frame>Assessed at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 10 and 12 hr post-dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration of Drug</measure>
    <time_frame>Assessed at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 10 and 12 hr post-dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>HIV/AIDS</condition>
  <arm_group>
    <arm_group_label>Generic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>generic fixed dose combination of Stavudine, Lamivudine and Nevirapine (Triomune)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brand</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 separate single pills of Zerit (Stavudine)Epivir (Lamivudine) Viramune (Nevirapine)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triomune</intervention_name>
    <description>Stavudine (40mg) Lamivudine (150mg) Nevirapine (200mg)All twice a day</description>
    <arm_group_label>Generic</arm_group_label>
    <other_name>Stavudine</other_name>
    <other_name>Lamivudine</other_name>
    <other_name>Nevirapine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zerit/Epivir/Viramune</intervention_name>
    <description>Stavudine (40mg) Lamivudine (150mg) and Nevirapine (200mg) All taken twice daily.</description>
    <arm_group_label>Brand</arm_group_label>
    <other_name>Stavudine</other_name>
    <other_name>Lamivudine</other_name>
    <other_name>Nevirapine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HIV-infected men and non-pregnant women;

          2. On Triomune for at least 4 weeks;

          3. 18 years or greater;

          4. Residing within 15km of Kampala city center

        Exclusion Criteria:

          1. Unable to sign or understand informed consent

          2. Concurrent medication known to interact with any of the components of Triomune

          3. Patients with active TB, malabsorption, nausea, emesis, abdominal discomfort, chronic
             diarrhoea, documented active clinically relevant hepatitis;

          4. Patients expected to change their drug regimen or dosage during the study

          5. Those planning to move out of Kampala in the next two months;

          6. Hemoglobin &lt;7.0 mmol/l (men) or &lt;6.5 mmol/l (women);

          7. Alanine aminotransferase or aspartate aminotransferase &gt;5 times the upper limit of
             normal;

          8. Serum creatinine &gt; 1.5 times the upper limit of normal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jayne Tusiime, B Pharm, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Makerere University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David R Bangsberg, MD,MPH</last_name>
    <role>Study Chair</role>
    <affiliation>Harvard University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Makerere University</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <results_reference>
    <citation>Byakika-Tusiime J, Chinn LW, Oyugi JH, Obua C, Bangsberg DR, Kroetz DL. Steady state bioequivalence of generic and innovator formulations of stavudine, lamivudine, and nevirapine in HIV-infected Ugandan adults. PLoS One. 2008;3(12):e3981. doi: 10.1371/journal.pone.0003981. Epub 2008 Dec 19.</citation>
    <PMID>19096711</PMID>
  </results_reference>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2009</study_first_submitted>
  <study_first_submitted_qc>November 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2009</study_first_posted>
  <results_first_submitted>April 21, 2009</results_first_submitted>
  <results_first_submitted_qc>November 3, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 4, 2009</results_first_posted>
  <last_update_submitted>December 31, 2009</last_update_submitted>
  <last_update_submitted_qc>December 31, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2010</last_update_posted>
  <responsible_party>
    <name_title>Jayne Tusiime</name_title>
    <organization>University of California, Berkeley</organization>
  </responsible_party>
  <keyword>HIV;Bioequivalence;Triomune</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
    <mesh_term>Stavudine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from an ongoing cohort study in Kampala, Uganda. The first subject was recruited in Feb 2006.</recruitment_details>
      <pre_assignment_details>Participants received a medical and laboratory examination before assignment. Subjects were excluded if they had active tuberculosis or were anemic. 22 participants were recruited; 22 were screened,2 were excluded (1 did not meet inclusion criteria and 1 refused participation).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Generic (Triomune) to Brand (Zerit/Epivir/Viramune)</title>
          <description>Started with generic formulation (Triomune) then switched to brand formulation (Zerit/Epivir/Viramune).</description>
        </group>
        <group group_id="P2">
          <title>Brand (Zerit/Epivir/Viramune) to Generic (Triomune)</title>
          <description>started with brand formulation(Zerit/Epivir/Viramune) then switched to generic formulation (Triomune)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Generic (Tr) First Then Brand (Ze/Ep/Vi)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period of 30 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Brand (Ze/Ep/Vi) First Then Generic (Tr)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entire Study Population</title>
          <description>Includes groups randomized to receive generic formulation and brand formulation</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.4" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.1" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.3" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-Time Curve(AUC)</title>
        <description>Mean Area Under the Plasma Concentration-Time Curve for each drug, log transformed</description>
        <time_frame>Assessed at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 10 and 12 hr post-dosing</time_frame>
        <population>Analyzed population consists only of participants who had sufficient plasma samples for analysis.Intent to treat analysis was used. Separate analyses provided for each drug. Results of such a study are not combined.</population>
        <group_list>
          <group group_id="O1">
            <title>Generic Stavudine</title>
            <description>period when subjects were on generic stavudine</description>
          </group>
          <group group_id="O2">
            <title>Brand Stavudine</title>
            <description>period when subjects were on brand stavudine</description>
          </group>
          <group group_id="O3">
            <title>Generic Nevirapine</title>
            <description>period when subjects were on generic nevirapine</description>
          </group>
          <group group_id="O4">
            <title>Brand Nevirapine</title>
            <description>Period when subjects were on brand nevirapine</description>
          </group>
          <group group_id="O5">
            <title>Generic Lamivudine</title>
            <description>period when subjects were on generic lamivudine</description>
          </group>
          <group group_id="O6">
            <title>Brand Lamivudine</title>
            <description>Period when subjects were on brand lamivudine</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-Time Curve(AUC)</title>
          <description>Mean Area Under the Plasma Concentration-Time Curve for each drug, log transformed</description>
          <population>Analyzed population consists only of participants who had sufficient plasma samples for analysis.Intent to treat analysis was used. Separate analyses provided for each drug. Results of such a study are not combined.</population>
          <units>hour*milligram/liter</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="2.4"/>
                    <measurement group_id="O2" value="3.4" spread="3.9"/>
                    <measurement group_id="O3" value="85.8" spread="35.2"/>
                    <measurement group_id="O4" value="79.2" spread="45.7"/>
                    <measurement group_id="O5" value="5.2" spread="2.5"/>
                    <measurement group_id="O6" value="6.4" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there is a difference in the relative bioavailability of Triomune and brand-name stavudine/lamivudine/nevirapine in HIV-infected Africans. 18 participants were required to provide 80% power to detect approximately a 20% difference on a log scale in AUC0-12h between the brand formulation and the generic formulation. Alpha level of 0.05.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence was defined as a 90% Confidence Interval of the geometric mean ratio between 0.8 and 1.25. Differences between treatments with respect to the outcome and intra- and inter-subject variances were assessed using the mixed effects model. Bootstrapped random errors were used.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.38</ci_upper_limit>
            <estimate_desc>the generic is the numerator while the brand is the denominator</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there is a difference in the relative bioavailability of Triomune and brand-name stavudine/lamivudine/nevirapine in HIV-infected Africans. 18 participants were required to provide 80% power to detect approximately a 20% difference on a log scale in AUC0-12h between the brand formulation and the generic formulation. Alpha level of 0.05.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence was defined as a 90% Confidence Interval of the geometric mean ratio between 0.8 and 1.25. Differences between treatments with respect to the outcome and intra- and inter-subject variances were assessed using the mixed effects model. Bootstrapped random errors were used.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
            <estimate_desc>the generic is the numerator while the brand is the denominator</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there is a difference in the relative bioavailability of Triomune and brand-name stavudine/lamivudine/nevirapine in HIV-infected Africans. 18 participants were required to provide 80% power to detect approximately a 20% difference on a log scale in AUC0-12h between the brand formulation and the generic formulation. Alpha level of 0.05.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence was defined as a 90% Confidence Interval of the geometric mean ratio between 0.8 and 1.25. Differences between treatments with respect to the outcome and intra- and inter-subject variances were assessed using the mixed effects model. Bootstrapped random errors were used.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>0.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
            <estimate_desc>the generic is the numerator while the brand is the denominator</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration of Drug</title>
        <description>Maximum concentration of drug in plasma that was attained post dosing</description>
        <time_frame>Assessed at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 10 and 12 hr post-dosing</time_frame>
        <population>Intention to treat analysis used including only participants with sufficient plasma samples for analysis. Separate analyses are given for each drug. Results for this kind of study are not combined.</population>
        <group_list>
          <group group_id="O1">
            <title>Generic Stavudine</title>
            <description>period when subjects were on generic stavudine</description>
          </group>
          <group group_id="O2">
            <title>Brand Stavudine</title>
            <description>period when subjects were on brand stavudine</description>
          </group>
          <group group_id="O3">
            <title>Generic Nevirapine</title>
            <description>period when subjects were on generic nevirapine</description>
          </group>
          <group group_id="O4">
            <title>Brand Nevirapine</title>
            <description>Period when subjects were on brand nevirapine</description>
          </group>
          <group group_id="O5">
            <title>Generic Lamivudine</title>
            <description>period when subjects were on generic lamivudine</description>
          </group>
          <group group_id="O6">
            <title>Brand Lamivudine</title>
            <description>Period when subjects were on brand lamivudine</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration of Drug</title>
          <description>Maximum concentration of drug in plasma that was attained post dosing</description>
          <population>Intention to treat analysis used including only participants with sufficient plasma samples for analysis. Separate analyses are given for each drug. Results for this kind of study are not combined.</population>
          <units>milligram/liter</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="1.1"/>
                    <measurement group_id="O2" value="1.3" spread="2.0"/>
                    <measurement group_id="O3" value="8.8" spread="3.1"/>
                    <measurement group_id="O4" value="8.4" spread="5.5"/>
                    <measurement group_id="O5" value="1.0" spread="0.5"/>
                    <measurement group_id="O6" value="1.3" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Same as for AUC</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>same as for AUC</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>1.71</ci_upper_limit>
            <estimate_desc>same as AUC</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Same for all three drugs.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>same for all three drugs.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
            <estimate_desc>Same for all three drugs.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Same for all three drugs.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Same for all three drugs.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>0.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
            <estimate_desc>Same for all three drugs.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Patients were in the study for 60 days and this is the period over which they were monitored for any adverse events.</time_frame>
      <desc>After 30 days of taking each formulation subjects were asked if they had experienced any unwanted effects since they started taking the study drug. Responses were recorded in their study charts. During the blood draw period patients were watched for any adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Entire Study Population</title>
          <description>Includes groups randomized to receive generic formulation and brand formulation</description>
        </group>
        <group group_id="E2">
          <title>Generic to Brand</title>
          <description>Started with generic formulation then switched to brand formulation</description>
        </group>
        <group group_id="E3">
          <title>Brand to Generic</title>
          <description>started with brand formulation then switched to generic formulation</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Stavudine (40mg) was used whereas currently it is Stavudine(30mg) that is recommended for usage. So our results may not be applicable to patients on Stavudine 30mg.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jayne Byakika Tusiime</name_or_title>
      <organization>University of California Berkeley</organization>
      <phone>1 510 219 7567</phone>
      <email>tusiimej@berkeley.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

